Esophagectomy Candidates and Considerations

Patient Selection Criteria

The National Comprehensive Cancer Network recommends upfront esophagectomy for physiologically fit patients with early-stage (stage I or II) localized esophageal cancer, including T1-T3 tumors without bulky nodal involvement, who can tolerate major surgery 1, 2, 3
Patients with early-stage disease (stage I or II) with tumors through T3 without bulky nodal involvement are considered appropriate candidates for upfront surgery 1, 2
Physiologically fit patients able to tolerate general anesthesia and major thoracic/abdominal surgery are suitable for upfront esophagectomy 3, 4
Patients with localized resectable thoracic esophageal cancer >5cm from cricopharyngeus are considered for upfront surgery 2, 5
Patients with intra-abdominal esophagus or esophagogastric junction (EGJ) cancer are considered for upfront surgery 3, 4
Selected patients with stage III disease without involvement of adjacent critical structures may be considered for upfront esophagectomy 1, 2
Patients with T4 tumors with involvement limited to pericardium, pleura, or diaphragm may be considered for upfront surgery 1, 2

Patients with cervical or cervicothoracic esophageal carcinomas <5cm from cricopharyngeus should receive definitive chemoradiation instead of upfront surgery 2, 3
Patients with supraclavicular lymph node involvement are not suitable for upfront esophagectomy 1, 2
Stage IV tumors with distant metastases or non-regional lymph node involvement are contraindications to upfront surgery 1, 2
T4 tumors with involvement of heart, great vessels, trachea, or adjacent organs (liver, pancreas, lung, spleen) are contraindications to upfront esophagectomy 1, 2
Patients with clearly unresectable disease or severe comorbidities (cardiac/pulmonary disease) are not candidates for upfront surgery 2, 3
Patients with bulky, multistation nodal involvement have a poor prognosis with surgery alone and are not suitable for upfront esophagectomy 1, 3

Clinical staging should include EUS (with FNA if indicated), chest and abdomen CT scan, and PET scan (integrated PET/CT preferred) for patients considered for upfront esophagectomy 3, 4
Laparoscopy should be considered for evaluation of resectability, especially for patients with large tumors involving the EGJ 1, 2
Nutritional assessment and support should be provided for patients with significant dysphagia and weight loss 2, 3
Multidisciplinary evaluation is essential for all patients with potentially resectable disease 3, 4

Esophagectomy should be performed in high-volume centers by experienced surgeons for optimal outcomes 3, 6
Lymph node dissection should aim to remove at least 15 lymph nodes for adequate staging in patients undergoing upfront surgery 1, 3
The surgical approach (transthoracic, transhiatal, or minimally invasive) depends on tumor location, size, and surgeon experience 5, 7
For Siewert type I and II EGJ tumors, the surgical approach is similar to esophageal cancer, while type III tumors are treated as gastric cancers 3, 4

Recent evidence suggests that perioperative chemotherapy or neoadjuvant chemoradiotherapy may be preferable to upfront surgery for locally advanced disease 8, 3
The CROSS study and MAGIC trial showed significant survival improvements with preoperative therapy for resectable esophageal and EGJ cancers 3, 4
Minimally invasive esophagectomy (MIE) may be associated with decreased morbidity and shorter recovery times compared to open procedures, particularly beneficial for older patients 2, 5

Lymph node involvement is a strong independent predictor of poor survival with surgery alone; these patients should be considered for multimodality therapy 3, 4
Open surgery should remain the standard for many patients, including those with previous abdominal surgery, large/bulky tumors, or when lymph node dissection may be difficult 2, 5
While MIE shows promising results, it remains investigational and requires surgeons with specific expertise 2, 5
Palliative resections should be avoided in patients with clearly unresectable disease or significant comorbidities 1, 2
For early-stage disease (T1a-T1b), endoscopic resection may be considered as an alternative to esophagectomy in selected cases 7